It sounds like science‑fiction, but the world of medicine has a long‑standing tradition of turning one disease into a cure for another. In fact, the very phrase 10 microorganisms pathogens captures a fascinating roster of microbes—bacteria, viruses, protozoa and even engineered cells—harnessed to battle illnesses that were once deemed hopeless. Below we dive into ten remarkable examples, each a testament to human ingenuity and the surprising ways nature can be coaxed into healing itself.
10 Microorganisms Pathogens Overview
From the fever‑inducing power of malaria to the high‑tech precision of CAR‑T cells, these ten microscopic agents demonstrate how the line between pathogen and remedy can blur. Let’s explore each case, complete with the back‑story, the science, and the outcomes that have reshaped modern therapeutics.
10 Malaria
Syphilis, a sexually transmitted infection that devastated populations for centuries, often progressed to neurosyphilis—a stage marked by blindness, madness, paralysis, and eventual death. Before antibiotics, sufferers were typically confined to asylums, awaiting a grim fate.
Austrian psychiatrist Dr. Julius Wagner‑Jauregg, working in the 1880s, sought a radical solution: pyrotherapy, the deliberate induction of high fever. He hypothesized that a manageable infection could spike body temperature enough to annihilate the syphilitic bacteria.
After fruitless attempts with tuberculosis antigen and typhus and typhoid vaccines, Wagner‑Jauregg’s breakthrough arrived in June 1917. A wounded soldier, mistakenly admitted to his psychiatric ward, carried malaria. Seizing the chance, the doctor extracted the soldier’s infected blood and injected it into nine advanced syphilis patients.
The introduced Plasmodium parasites provoked a severe fever, raising the body’s temperature to the point where the syphilis‑causing Treponema pallidum could not survive. Six of the nine patients survived the malaria episode and were subsequently cured of syphilis; they later received quinine to eliminate the malaria infection.
In 1918, Wagner‑Jauregg published his findings, noting that a sustained temperature of 41 °C (106 °F) for six hours eradicated syphilis. His method quickly became the preferred treatment, though it carried significant risks.
Complications included transfusion reactions from mismatched blood types, transmission of donor blood diseases, and severe anemia or kidney failure from the virulent malaria strain. Over time, physicians switched to the milder P. vivax strain, and the therapy was eventually abandoned after antibiotics rendered it unnecessary.
9 HIV
It may sound paradoxical, but researchers have turned the world’s most notorious virus—HIV—into a delivery vehicle for gene therapy, aiming to cure rare genetic disorders such as leukodystrophy and Wiskott‑Aldrich syndrome, both of which primarily affect children.
The key isn’t the virus itself but a specially engineered viral vector derived in part from HIV. These vectors act like molecular couriers, ferrying therapeutic genes into a patient’s cells. In 2010, an Italian team led by Dr. Luigi Naldini administered such HIV‑based vectors to 16 children: six with Wiskott‑Aldrich syndrome and ten with leukodystrophy.
Three years later, the investigators reported encouraging signs of recovery. Six of the children—three from each disease group—showed measurable improvements, while the remaining ten also exhibited early positive trends. Though still under clinical investigation, these results hint at a future where a virus once feared can become a life‑saving tool.
8 Cancer
CRISPR, an acronym for “Clustered Regularly Interspaced Short Palindromic Repeats,” has revolutionized gene editing. While many scientists focus on correcting faulty genes, researchers at the Rutgers Cancer Institute of New Jersey have taken a bold approach: using CRISPR to weaponize cancer cells against themselves.
The team engineered tumor cells to produce a protein called S‑TRAIL, which triggers apoptosis (programmed cell death) in neighboring cancer cells. Once injected back into a mouse model, these modified cells migrated to the original tumor site, released S‑TRAIL, and caused surrounding cancer cells to self‑destruct.
Pre‑clinical trials in mice have shown promising tumor shrinkage, but human testing has yet to begin. If successful, this strategy could turn a patient’s own malignancy into a Trojan horse, delivering a lethal payload directly to the disease.
7 Cowpox
The cowpox virus earned its place in history as the foundation of modern vaccination. Though the smallpox virus ravaged humanity for millennia, the related cowpox virus—derived from the Latin word *vaccinus* meaning “cow”—provided a natural antidote.
Long before Edward Jenner’s famous experiments, ancient Chinese and Middle Eastern healers deliberately exposed themselves to cowpox to gain immunity against smallpox. Jenner, an English physician, observed that milkmaids rarely contracted smallpox, deducing that their exposure to cowpox granted protection.
In 1796, Jenner tested his hypothesis by inoculating eight‑year‑old James Phipps with cowpox material. After a month and a half, Jenner exposed Phipps to smallpox; the boy remained disease‑free, confirming that cowpox conferred immunity. This breakthrough led to the development of the vaccinia virus–based vaccine, ultimately eradicating smallpox in 1977.
6 Poliovirus
Poliovirus, the agent behind the crippling disease polio, has been driven to the brink of extinction thanks to global vaccination campaigns. Yet scientists have found a novel, paradoxical use for this once‑deadly virus: treating glioblastoma, an aggressive brain tumor.
Researchers at Duke Cancer Institute engineered a modified poliovirus, dubbed PVSRIPO, which selectively infects and destroys glioblastoma cells while sparing healthy brain tissue. The virus is directly injected into the tumor, where it replicates and triggers an immune response against the cancer.
In a Phase I trial involving 61 patients, PVSRIPO achieved a 21 % one‑year survival rate—substantially higher than the 4 % survival associated with standard therapies. Nevertheless, the treatment carries risks, including inflammation and other side effects depending on tumor location.
5 Bacteriophage Therapy
In 2015, 69‑year‑old Tom Patterson traveled to Egypt and was diagnosed with pancreatitis. Conventional treatments failed, and further tests in Frankfurt revealed a drug‑resistant infection with Acinetobacter baumannii. When the infection spread to his bloodstream, Patterson fell into a two‑month coma.
Desperate physicians turned to bacteriophage therapy—a method that employs viruses that specifically target bacteria. Unlike antibiotics, bacteriophages (literally “bacteria eaters”) latch onto bacterial cells, inject their genetic material, and hijack the host to produce more viruses, ultimately lysing the bacterium.
After several rounds of tailored phage administration, Patterson’s condition improved, and he emerged from the coma. However, the infecting A. baumannii strain later evolved resistance, prompting doctors to isolate a newer phage variant that finally cleared the infection.
4 Maraba Virus
The Maraba virus, also known as MG1, has long been recognized for its ability to destroy cancer cells. Recent investigations by scientists at the Ottawa Hospital and the University of Ottawa have uncovered an additional, unexpected capability: targeting HIV‑infected cells.
HIV resides primarily in immune cells, where it can enter a dormant state, evading antiretroviral drugs. When treatment stops, these latent reservoirs reactivate, leading to viral rebound.
Laboratory experiments demonstrated that the Maraba virus preferentially infects and kills dormant HIV‑infected cells, offering a potential avenue toward a functional cure. So far, the work remains confined to cell culture; animal and human studies are still pending.
3 Coley’s Toxin Treatment
In the late 19th century, New York bone surgeon William Coley observed that cancer patients who contracted bacterial infections after surgery often experienced tumor regression. He hypothesized that the immune activation triggered by the infection was responsible for this effect.
To harness this phenomenon, Coley began injecting patients with live bacteria, later switching to killed bacterial preparations to reduce risk. The treatment, known as Coley’s toxin, aimed to stimulate the immune system to recognize and attack cancer cells.
Scientists remain divided on the exact mechanism: some argue the bacterial components boost immune surveillance, while others suggest they induce the production of cytokines such as interleukin‑12 or tumor necrosis factor, both of which can target malignancies. Another theory points to fever‑induced tumor cell death, echoing the earlier pyrotherapy approach.
Although Coley’s toxin yielded mixed outcomes—benefiting some patients while failing in others—it became a widely used cancer therapy until the 1950s, when chemotherapy and radiation took precedence. Modern research continues to explore genetically engineered bacteria as a refined version of Coley’s original concept.
2 Predatory Bacteria
Predatory bacteria are a unique class of microorganisms that hunt and consume other bacteria. They breach the prey’s cell wall, infiltrate the interior, devour its contents, and reproduce, leaving behind a wave of destruction against harmful microbes.
Scientists are exploring their potential as living antibiotics, especially against multidrug‑resistant “superbugs.” In November 2016, researchers at Imperial College London and the University of Nottingham reported that Bdellovibrio bacteriovorus could dramatically reduce populations of Shigella, a pathogen responsible for severe food‑borne illness.
In laboratory experiments, exposure to B. bacteriovorus lowered Shigella counts by a factor of 4,000. Further testing in fish larvae showed survival rates jump from 25 % to 60 % when the predatory bacteria were introduced. Ongoing studies aim to assess efficacy against other dangerous bacteria such as Salmonella and E. coli.
1 CAR‑T Therapy
T‑cells, a cornerstone of the adaptive immune system, have been re‑engineered in a groundbreaking approach called chimeric antigen receptor T‑cell therapy, or CAR‑T. This personalized treatment extracts a patient’s own T‑cells, modifies them to express synthetic receptors that recognize specific cancer markers, and reinfuses them to hunt down malignant cells.
The engineered receptors dramatically enhance the T‑cells’ ability to bind to, infiltrate, and destroy cancer cells, effectively turning the patient’s immune system into a precise, living drug. CAR‑T therapy has shown remarkable success against certain blood cancers, offering hope where conventional treatments have failed.
Despite its promise, CAR‑T therapy remains a last‑line option due to significant side effects, including cytokine release syndrome and neurotoxicity. Moreover, the manufacturing process is labor‑intensive, often taking up to four months to produce a patient‑specific product.